Armistice Capital, LLC's Form 4 filing
Avalo Therapeutics, Inc.AVTX · filed Feb 9, 2023
- Accession no.
- 0000899243-23-004412
- Filed
- Feb 9, 2023, 4:32 PM ET
- Trade date
- Feb 3-7, 2023
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armistice Capital, LLCCIK 0001601086 | 10% Owner |
| Armistice Capital Master Fund Ltd.CIK 0001633584 | 10% Owner |
| Boyd StevenCIK 0001706140 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2023 | Common Stock | LLess common codeAcquired | +334 | $3.95 | +$1,319.3 | 3,965,000 | Indirect | |
| Feb 7, 2023 | Common Stock | PPurchaseAcquired | +450,000 | –F3 | – | 4,415,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 7, 2023 | Common Stock | PPurchaseAcquired | +450,000 | –F4 | – | 450,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Each share of common stock and accompanying warrant were purchased together for $3.98. The warrants are subject to a 4.99% beneficial ownership limitation on exercise.
Referenced by the price of 1 transaction in Table I.
- F4
These shares are directly owned by Mr. Boyd in his personal capacity.
Referenced by the price of 1 transaction in Table II.